Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. The company's pipeline includes emavusertib (CA-4948), an IRAK4 kinase inhibitor, and fimepinostat (CI-8993), a dual inhibitor of PI3K and HDAC, targeting VISTA. Curis is dedicated to advancing novel drug candidates that have the potential to make a meaningful difference in the lives of patients with cancer.
The headquarters serves as the central hub for Curis's research and development operations, clinical development, corporate administration, and strategic planning.
Modern office park setting optimized for biotech research and collaboration, providing advanced laboratory and office spaces.
The work culture at Curis's headquarters is dynamic and science-driven, fostering innovation, collaboration, and a strong sense of purpose among its teams dedicated to oncology research. It reflects the fast-paced and mission-oriented environment typical of the biotech industry.
Its location in the Boston/Cambridge biotech cluster provides Curis with access to a rich ecosystem of talent, leading research institutions, and potential industry collaborators, which is crucial for a company focused on cutting-edge cancer therapeutics.
Curis, Inc. establishes its global presence primarily through its clinical development programs. The company conducts clinical trials for its oncology drug candidates in multiple countries, collaborating with research institutions and healthcare providers worldwide. This international approach is essential for gathering diverse patient data and advancing its therapies towards potential regulatory approval and commercialization in various markets.
128 Spring Street, Suite 500
Lexington
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Curis' leadership includes:
Curis has been backed by several prominent investors over the years, including:
Curis experienced a key transition in its financial leadership over the past year, with the departure of its CFO in late 2023 and the subsequent appointment of a new CFO in early 2024.
Discover the tools Curis uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Curis, Inc. commonly utilizes an email format that combines the first initial of an employee's name with their last name, followed by the company domain '@curis.com'. This is a frequent pattern in many corporations.
[first_initial][last]@curis.com
Format
jdoe@curis.com
Example
80%
Success rate
GlobeNewswire • May 7, 2024
Curis announced its financial results for Q1 2024, highlighting progress in its clinical programs for emavusertib and fimepinostat, and outlining its strategic priorities for advancing its oncology pipeline....more
GlobeNewswire • February 27, 2024
Curis announced the appointment of Diantha Duvall as its new CFO, bringing over 20 years of biopharmaceutical financial experience to the company, effective February 26, 2024....more
GlobeNewswire • January 4, 2024
Curis provided an update on its TakeAim Lymphoma study for emavusertib, detailing enrollment progress, initial clinical data, and strategic plans for the development in patients with B-cell malignancies....more
GlobeNewswire • September 26, 2023
Curis announced that Richard Muhammad, Chief Financial Officer, would be leaving the Company, effective October 13, 2023, to pursue another opportunity. The company initiated a search for a new CFO....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Curis, are just a search away.